Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

January 01, 1996; 46 (1) Article

Association of the mitochondrial 8344 MERRF mutation with maternally inherited spinocerebellar degeneration and Leigh disease

N. Howell, I. Kubacka, R. Smith, F. Frerman, J. K. Parks, W. D. Parker
First published January 1, 1996, DOI: https://doi.org/10.1212/WNL.46.1.219
N. Howell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Kubacka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Frerman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. K. Parks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. D. Parker Jr, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Association of the mitochondrial 8344 MERRF mutation with maternally inherited spinocerebellar degeneration and Leigh disease
N. Howell, I. Kubacka, R. Smith, F. Frerman, J. K. Parks, W. D. Parker
Neurology Jan 1996, 46 (1) 219-222; DOI: 10.1212/WNL.46.1.219

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
50

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Article abstract-We report previously undescribed or atypical clinical and biochemical manifestations of the mitochondrial DNA MERRF mutation at nucleotide 8344 in members of a multigenerational family with a maternally inherited, highly variable neurodegenerative disorder. The more profound neurologic abnormalities include Leigh disease, spinocerebellar degeneration, and atypical Charcot-Marie-Tooth disease.

NEUROLOGY 1996;46: 219-222

MERRF, myoclonic epilepsy with ragged-red fibers, is one of the mitochondrial encephalopathies, a clinically diverse group of disorders that also includes Kearns-Sayre syndrome (KSS) and MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes). [1,2] In many cases, these disorders involve a mutation within the mitochondrial genome as the primary etiologic factor. MERRF is usually causatively associated with a mutation at nucleotide 8344 in the mitochondrial tRNAlys gene, although there is one report of a matrilineal MERRF pedigree that carried a mutation in the same gene at nucleotide 8356. [3]

We report here the clinical and molecular genetic analysis of a family who carry the 8344 MERRF mutation, but who exhibit an array of neurologic disorders previously unassociated with this mitochondrial mutation. It was initially thought that the inheritance was autosomal dominant, [4] but the clinical abnormalities have been maternally transmitted through three generations, thereby alerting us to the possibility of mitochondrial inheritance.

Clinical findings.

The pedigree of this family displays a multigenerational neurologic disorder that is striking in terms of both phenotypic variability and age of onset (Figure 1).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Pedigree of a family with suspected maternal transmission of diverse neurologic abnormalities including Leigh disease and spinocerebellar degeneration.

Patient I-1.

This woman, a Cherokee Indian, became physically debilitated and unable to care for her two children at about age 20 years. According to the recollections of family members, she had symptoms compatible with ataxia, and she died at about age 40 years after being chronically bedridden. The presumptive diagnosis was spinocerebellar degeneration, but no autopsy was performed.

Patient II-1.

This woman had a late childhood onset of mild ataxia, which had been only questionably progressive. She remained ambulatory at age 73 years. In addition to ataxia, she had mild pes cavus changes, pyramidal tract findings, and a painful distal sensory loss in a stocking-and-glove distribution. The ataxia predated the neuropathy, and there was truncal ataxia not explained by the distal sensory loss. She also had tachycardia and multiple cutaneous lipomas.

Patient II-2.

This man developed a severe motor unit disorder, ataxia, and central hypoventilation in the fifth decade of life that was diagnosed as "cerebellar degeneration." Progressive encephalopathy developed, and he died bedridden at age 58 years. The autopsy diagnosis (performed 18 years ago) was atypical Charcot-Marie-Tooth disease; degeneration of anterior horn cells was noted. The tissue blocks from the autopsy have not been located for re-review.

Patient III-2.

This 45-year-old man had been fully functional in a physically demanding profession. However, he had cutaneous lipomas, a loss of visual acuity that in recent years was not fully corrected by refractive changes, a long history of muscle cramps, and occasional myoclonic "jerks," especially when excited. He had never been able to perform tandem gait, even in childhood.

Patient III-3.

This patient had an onset of progressive ataxia in early childhood. At age 45 years, she was ambulatory with assistance. Station and gait testing revealed a wide-based gait with intorsion of the shoulders into a dystonic posture when walking. She was areflexic and had bilateral Babinski signs, pes cavus changes, and multiple cutaneous lipomas. There was a mild loss of distal limb sensation as well as dysarthria, hearing impairment, and mood lability. Cranial nerve function was normal except that she could not converge her gaze. She had a hypertrophic cardiomyopathy and a history of tachycardia. Optic atrophy was present, but visual fields were full, and there was no evidence of retinitis pigmentosa. MRI showed severe generalized atrophy of the spinal cord and less severe atrophy of the cerebral cortex.

Patients IV-1 and -2.

Both were clinically normal (ages 21 and 23 years).

Patient IV-3.

This patient died at age 10 months of respiratory failure secondary to primary central hypoventilation. He had lactic acidosis, optic atrophy, myoclonic seizures, skeletal myopathy, and hypertrophic cardiomyopathy.

Patient IV-4.

This patient died at about age 4 from chronic respiratory failure secondary to primary central hypoventilation. He had skeletal myopathy and hypertrophic cardiomyopathy by echocardiogram. Lactic acidosis was present. Muscle biopsy showed only nonspecific changes. The diagnosis was Leigh disease at autopsy on the basis of typical lesions in basal ganglia and brainstem.

Methods.

Molecular genetic analysis of the mitochondrial genome from family members was carried out with the strategy used routinely in our studies. [5] All procedures were conducted under a protocol approved by an institutional review board and with informed consent of the patients. Briefly, total DNA was isolated from either primary fibroblast cultures or platelets, and this DNA was then used for PCR amplification of short fragments (approximately 300 bp) of the mitochondrial genome with pairs of primers that contained Sau3A restriction endonuclease sites. After purification and Sau3A digestion of the amplified DNA fragments, they were cloned into BamH1-cleaved M13 sequencing vectors and transformed into an Escherichia coli host strain. Recombinant plasmids were used for dideoxy chain termination nucleotide sequencing. A cumulative span of about 4,000 bp of the mitochondrial genome coding region has been sequenced for members of this maternal lineage. The regions analyzed spanned the sites of previously identified pathogenetic mutations; these included the entire length of the tRNAleu, tRNAlys, cytochrome b, and ATPase6 genes. Finally, for each mtDNA region, the sequence from at least two maternal relatives was determined.

Mitochondria were prepared as previously described from platelets obtained by plateletpheresis. [6] The concentration of cytochrome b was determined from dithionite-reduced minus oxidized spectra in a Shimadzu UV-3000 spectrophotometer at 25 degrees C after solubilization with n-dodecyl-beta-D-maltoside (Boehringer-Mannheim).

Results.

Because the maternal transmission of the neurologic abnormalities in this family (Figure 1) suggested mitochondrial inheritance, rather than nuclear, we investigated the possibility of a pathogenetic mutation in the mitochondrial DNA. The DNA sequencing analysis showed that the three members of this matrilineal pedigree who were tested carry the 8344 MERRF mutation (Table 1). The mutation was heteroplasmic in all three family members and in DNA from both platelets and fibroblasts. As anticipated, the proportion of the 8344 mutant allele was highest in the most severely affected family member (III-3). Previous studies have indicated a correlation between the proportion of the 8344 mutation and the severity of clinical symptoms. [7,8] However, this trend is not absolute, the proportion of the mutant allele in platelet mtDNA was higher in the minimally affected brother (III-2) than in his more severely affected mother (II-2). The proportion of the 8344 mutation should have been very high in the tissues of the two sons, IV-3 and IV-4, because they were the most severely affected. Unfortunately, no tissue was available to test this prediction.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1. Tissue distribution of the 8344 mutation

Other than the MERRF mutation at nucleotide 8344, none of the other changes from the Cambridge standard sequence were likely to be pathogenetic because they were phenotypically silent or were polymorphisms that had been detected previously in normal controls (data not shown). For example, the nucleotide sequence of the entire cytochrome b gene was determined for three family members. The only sequence difference from the Cambridge standard was an AT[arrow right]GC transition at nucleotide 15326, a polymorphism observed in more than 95% of the subjects whom we have analyzed.

Prior to the mitochondrial genetic analysis, biochemical assays were carried out with platelet mitochondria to ascertain whether the clinical symptoms in this matrilineal lineage were associated with respiratory chain dysfunction. In an attempt to minimize spurious results arising from the relatively harsh conditions required for isolation of platelet mitochondria, and to normalize activity to an intrinsic mitochondrial membrane redox protein, alpha-glycerophosphate:cytochrome c oxidoreductase flux was titrated as a function of the concentration of antimycin or myxothiazol [6] respiratory chain inhibitors that bind to the protonmotive cytochrome b subunit of Complex III. [9] This assay measures the ubiquinone-mediated transfer of reducing equivalents from the flavin-linked mitochondrial alpha-glycerophosphate dehydrogenase to Complex III (ubiquinol:cytochrome c oxidoreductase). The flux values were then normalized to the concentration of cytochrome b. The results of these experiments (Figure 2) show that there is a slight increase in both antimycin and myxothiazol resistance in mitochondria isolated from minimally affected (III-2) and severely affected (III-3) family members, but not in those from the clinically normal daughter (IV-2) of III-2.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Titration curves of alpha-glycerophosphate-cytochrome c oxidoreductase activity as a function of antimycin (open symbols) and myxothiazol (filled symbols). (A) Results for mitochondria from a single control subject (circles) and for the pooled results from assays of a group (n = 5) of normal subjects (squares). (B) MERRF family member III-2. (C) MERRF family member III-3. (D) MERRF family member IV-2. It should be noted that family member IV-2 (D) is the clinically normal daughter of male family member III-2 (C) and that she does not carry the 8344 MERRF mutation (data not shown).

Discussion.

This family illustrates two important results that often confound the clinical, biochemical, and molecular genetic analysis of the mitochondrial encephalomyopathies. First, maternal transmission of the disorder was problematic because of the small size of the pedigree and the marked variability in the clinical symptoms. Second, although this family has some of the abnormalities that typify MERRF patients, including lipomas, other features were atypical. For example, Leigh syndrome is an infrequent occurrence in patients with the 8344 MERRF mutation. [10] Furthermore, to our knowledge, this is the first instance of an association of spinocerebellar degeneration, in the absence of pronounced myoclonus and seizures, with this pathogenetic mitochondrial DNA mutation. Greenwood et al [11] reported a small family with both Leigh disease and spinocerebellar degeneration among the members. It would be of interest to screen this family for mitochondrial mutations, particularly those that cause MERRF. The neurologic deficits in that family [11] were characterized as autosomal dominant, but the transmission is also compatible with maternal inheritance, and there were elevated CSF lactate/pyruvate ratios. There is also a recent report of a patient with Ekbom's syndrome. [12] Both ataxia and neuropathy were present in association with the 8344 mutation, but there was no spontaneous or evoked myoclonus in this patient.

No biochemical or mtDNA sequence data are available for patient II-2, but we hypothesize that his late-onset, atypical Charcot-Marie-Tooth disease may represent yet another phenotype associated with the 8344 MERRF mutation. Patient III-2, who carries the 8344 mutation at an unexpectedly high level in blood and fibroblasts and who apparently has a respiratory chain defect (Figure 2), is mildly affected at the present time. Whether or not he will develop a similar neurodegenerative condition later in life is unknown, but the present studies support the possibility of long latencies of mitochondrial neurodegenerative diseases.

The biochemical assays of respiratory chain function were illustrative of the difficulties encountered in the analysis of the mitochondrial encephalopathies, and they underscore the value of integrated genetic, biochemical, and clinical studies. At first consideration, the increase in myxothiazol and antimycin resistance (Figure 2) suggested that, in the members of this maternal lineage, there was a reduction in the binding of these inhibitors to the mitochondrially encoded cytochrome b subunit of Complex III. However, the results of nucleotide sequencing revealed unequivocally that there were no mutations in the mitochondrial cytochrome b gene, thus obviating a direct explanation for the increased inhibitor resistance. On the basis of previous studies with yeast mutants that showed increased resistance to the Complex III inhibitor diuron in assays of NADH-cytochrome c oxidoreductase, [13] an explanation can be put forward that resolves this apparent paradox. In brief, the alphaglycerophosphate:cytochrome c oxidoreductase assay involves two redox enzyme complexes "connected" by a ubiquinone pool. Furthermore, the overall rate of electron transfer is limited by the rate at which the dehydrogenase complex reduces the quinone intermediates (Vred), not by the rate at which Complex III reoxidizes these intermediates (Vox). As one consequence of the complex kinetics of this assay, a decrease in the flux rate through Complex III will increase the measured antimycin and myxothiazol resistance (figure 4 of [13]). The results in Figure 2, therefore, most likely reflect Complex III dysfunction in platelet mitochondria, although more detailed studies will be required to confirm this conclusion. Interestingly, other studies have also obtained evidence for mitochondrial Complex III deficiencies in MERRF patients. [14]

The prevailing explanation for the marked clinical variability among the mitochondrial encephalomyopathies (MERRF, MELAS, KSS) is differential, local neurodegeneration within the CNS due to mitochondrial respiratory chain dysfunction. [1,2] The pathophysiology is a complex function of several determinant factors. On the one hand, there will be genetic factors that include the phenotype of the mitochondrial mutation and its genetic "load" (eg, the proportion of the mutant allele when heteroplasmic) in different regions of the CNS. In addition, however, there are also important physiologic and developmental factors that result in a "selective regional vulnerability within the nervous system." [15] In the example of MERRF, the pathology is relatively diffuse, but there is neuronal loss in the cerebellar dentate nucleus and brainstem. Although cerebral cortical pathologic lesions are absent, Thompson et al [16] reported that, irrespective of the severity of myoclonus in 8344 MERRF patients, there is a common pattern of abnormal somatosensory evoked potentials consistent with cortical reflex myoclonus. Future studies of the mutant allele frequency in local areas of the CNS, particularly of the cortex, in these patients may help to clarify the neuropathology and, from this knowledge, to develop more effective therapeutic strategies. The occurrence of atypical 8344 MERRF families, as exemplified by the present report, is a further indication that mitochondrial encephalomyopathies have probably been underdiagnosed when purely clinical criteria were used. Therefore, molecular genetic screening of a broad range of patients is amply justified. In particular, the 8344 mutation should be considered when evaluating patients with Leigh syndrome, unusual spinocerebellar degenerations, or unusual neuropathies.

Acknowledgments

The technical assistance of Ms. Toyya Kinsey in the nucleotide sequencing is gratefully acknowledged. We thank the patients who participated in this research.

  • Copyright 1996 by Advanstar Communications Inc.

REFERENCES

  1. 1.↵
    Matthews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993;43:2484-2490.
    OpenUrl
  2. 2.
    Sparaco M, Bonilla E, DiMauro S, Powers JM. Neuropathology of mitochondrial encephalomyopathies due to mitochondrial DNA defects. J Neuropathol Exp Neurol 1993;52:1-10.
    OpenUrlPubMed
  3. 3.↵
    Brown MD, Wallace DC. Molecular basis of mitochondrial DNA disease. J Bioenerg Biomember 1994;26:273-289.
    OpenUrl
  4. 4.↵
    Guggenheim MA, Stumpf DA. Familial metabolic disease with clinicopathological findings of both Leigh's disease and adulttype spinocerebellar degeneration. Ann Neurol 1977;2:264-265.
    OpenUrl
  5. 5.↵
    Howell N, Kubacka I, Xu M, McCullough DA. Leber hereditary optic neuropathy: involvement of the mitochondrial ND1 gene and evidence for an intragenic suppressor mutation. Am J Hum Genet 1991;48:935-942.
    OpenUrl
  6. 6.↵
    Parker WD Jr, Frerman F, Haas R, Parks JK. Myxothiazol resistance in human mitochondria. Biochim Biophys Acta 1988;936133-138.
  7. 7.↵
    Hammans SR, Sweeney MG, Brockington M, et al. The mitochondrial DNA transfer RNA sup lys A > G sup (8344) mutation and the syndrome of myoclonic epilepsy with ragged red fibres (MERRF): relationship of clinical phenotype to proportion of mutant mitochondrial DNA. Brain 1993;116:617-632.
    OpenUrl
  8. 8.
    Silvestri G, Ciafaloni E, Santorelli FM, et al. Clinical features associated with the A > G transition at nucleotide 8344 of mtDNA ("MERRF mutation"). Neurology 1993;43:1200-1206.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Howell N, Robertson DE. Electrochemical and spectral analysis of the long-range interactions between the Q sub o and Q sub i sites and the heme prosthetic groups in ubiquinol-cytochrome c oxidoreductase. Biochem 1993;32:11162-11172.
    OpenUrl
  10. 10.↵
    Sweeney MG, Hammans SR, Duchen LW, et al. Mitochondrial DNA mutation underlying Leigh's syndrome: clinical, pathological, biochemical, and genetic studies of a patient presenting with progressive myoclonic epilepsy. J Neurol Sci 1994;121:57-65.
    OpenUrl
  11. 11.↵
    Greenwood RS, DeVivo DC, Nelson JS, et al. An autosomal dominant form of necrotizing encephalomyelopathy resembling a spinocerebellar degeneration. Trans Am Neurol Assoc 1975;100:47-51.
    OpenUrl
  12. 12.↵
    Calabresi PA, Silvestri G, DiMauro S, Griggs RC. Ekbom's syndrome: lipomas, ataxia, and neuropathy with MERRF. Muscle Nerve 1994;17:943-945.
    OpenUrlPubMed
  13. 13.↵
    Meunier B, Colson-Corbisier A-M, Lemesle-Meunier D. Nuclearly inherited diuron-resistant mutations conferring a deficiency in the NADH- or succinate - ubiquinone oxidoreductase activity in Saccharomyces cerevisiae. Eur J Biochem 1989;184:651-656.
    OpenUrl
  14. 14.↵
    Berkovic SF, Carpenter S, Evans A, et al. Myoclonus epilepsy and ragged-red fibres (MERRF). 1. A clinical, pathological, biochemical, magnetic resonance spectrographic and positron emission tomographic study. Brain 1989;112:1231-1260.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Cavanagh JB, Harding BN. Pathogenic factors underlying the lesions in Leigh's disease: Tissue responses to cellular energy deprivation and their clinico-pathological consequences. Brain 1994;117:1357-1376.
    OpenUrlFREE Full Text
  16. 16.↵
    Thompson PD, Hammans SR, Harding AE. Cortical reflex myoclonus in patients with the mitochondrial DNA transfer RNA sup lys(8344) (MERRF) mutation. J Neurol 1994;241:335-340.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Clinical findings.
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise